Trial Profile
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; Inbakicept (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms QUILT-3.032
- Sponsors ImmunityBio
- 05 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2024 According to an ImmunityBio media release, data from this study were published by the peer-reviewed journal Urology Practice.
- 05 Feb 2024 Results (May 16, 2022 data cutoff) published in an ImmunityBio Media Release.